NCT01262235View on ClinicalTrials.gov

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

July 31, 2015

Study Completion Date

August 31, 2015

Conditions
CancerNeuroendocrine TumorsNETAdrenocortical CarcinomaACC
Interventions
DRUG

TKM-080301

Repeat dose IV infusion.

Trial Locations (8)

33612

Moffitt Cancer Center, Tampa

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

55905

Mayo Clinic, Rochester

77042

Westchase Oncology Center, Houston

85258

Scottsdale Healthcare Research Institute, Scottsdale

85259

Mayo Clinic Arizona, Scottsdale

02215

Dana Farber Cancer Institute, Boston

48109-2800

University of Michigan Comprehensive Cancer Center, Ann Arbor

Sponsors
All Listed Sponsors
lead

Arbutus Biopharma Corporation

INDUSTRY

NCT01262235 - A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | Biotech Hunter | Biotech Hunter